
|Articles|May 4, 2021
ODs: Here's what your patients tweeted about you in April 2021
Author(s)Brooke Henson, Editor
Find out what your patients are tweeting about you
Advertisement
Advertisement
Related to this article

Yuvezzi’s Health Canada submission leads this week’s recap, plus AI front desks, the EMERALD trial, and Alberta’s scope expansion.

Polygenic risk scores predicted glaucoma onset and treatment course better than family history alone in a 400,000-person biobank.

The phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.

The school will be admitting its inaugural Doctor of Optometry class in summer 2027, with full accreditation possible in 2030-31.

The FDA approved the Supplemental New Drug Application for phentolamine 0.75% (Ryzumvi, Opus Genetics/Viatris) to treat presbyopia.

Will AI reinvent the way patients book appointments in the next 5 years? Raphael Rostenne weighs in in the season 2 finale of The Independent Advantage.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
High Point University optometry school earns ACOE preliminary approval
2
Tenpoint Therapeutics submits NDS for Yuvezzi presbyopia drop to Health Canada
3
Takeaways from this week in optometry: November 16-20
4
Polygenic risk flags patients likely to need more glaucoma treatment
5


